

**Minutes of the Extraordinary General Meeting of Shareholders no.1/2021**

**Time and Venue** Extraordinary General Meeting of Shareholders no.1/2021 of Business Alignment Public Company Limited (“the company”) which held on Monday, October 18, 2021 at 2:00 pm at Conference Hall 1-2 Sathornthani Building 2, 2 Fl., Silom, Bangrak Bangkok 10500.

There were shareholders attending the meeting in person and the proxy are as follows.

- Attending the meeting in person 25 persons total of 277,797,083 shares
  - Attending the meeting by proxy 30 persons total of 20,606,440 shares
- Totaling of shareholders who attend the meeting 55 persons total of 298,403,523 shares or 74.6009% of the total number of shares sold. A quorum was thus constituted.

Mr. Woodtipong Moleechad was the Chairman of the meeting. Ms. Srisunun Anuchornphan as Company Secretary recorded the minutes of this meeting.

1. The Board of Directors are 7 persons attended the meeting total 7 persons or 100% of Board of Directors as follows:

- |    |                             |   |
|----|-----------------------------|---|
| 1. | Mr. Woodtipong Moleechad    | Chairman of the Board<br>Independent Directors  |
| 2. | Mr. Sompong Chunekitayanone | Director<br>Executive Chairman<br>Chief Executive Officer<br>Nomination and Remuneration Committee<br>Chairman of Risk Management Sub-Committee |
| 3. | Ms. Srirat Chuchottaworn    | Independent Director<br>Chairman of Audit Committee<br>Nomination and Remuneration Committee  |
| 4. | Mr. Vipoota Trakulhoon      | Independent Director<br>Audit Committee<br>Chairman of Nomination and Remuneration Committee  |
| 5. | Mr. Thanawat Lertwattanak   | Independent Director<br>Audit Committee<br>Nomination and Remuneration Committee  |
| 6. | Mr. Voravid Silapusid       | Director<br>Executive Committee<br>Chief Financial Officer<br>Nomination and Remuneration Committee<br>Risk Management Sub-Committee            |
| 7. | Mr. Noppadol Suntanaphanich | Director<br>Executive Committee<br>Risk Management Sub-Committee<br>Chief Quality Officer   |

Executive Committee who attended the meeting

Ms. Sukanlaya Khamnuan	Executive Committee Deputy Chief Financial Officer
------------------------	---

Financial Advisor

Mr. Seksan Tanopajai	Financial Advisor
Ms. Nuntarat Sangsuwannukul	Financial Advisor

Legal Advisor

Ms. Choladda Busabong	Legal Advisor
Mr. Nakrittayos Vachiravarakan	Legal Advisor

Company Secretary

Ms. Srisunun Anuchornphan	Company Secretary
---------------------------	-------------------

This Extraordinary Meeting of Shareholders was accordance with the resolution of the Board of Directors' meeting held on September 10, 2021, to consider the agendas as stated in the invitation letter. The record date of the company shares register book for determining the right to attend the meeting will be on September 27, 2021, in order to determine the shareholders' entitlement to attend the Extraordinary General Meeting of Shareholders 1/2021, the total number of shareholders was 3,095 shareholders.

The company uses the bar code registration and voting systems for facilitate the shareholders. The shareholders who registered will receive a ballot for each agenda from the staff at the registration point in the form of paper perforation. Agenda 5 is to consider the appointment of directors who retire by rotation. It is a separate vote for the appointment of a director and will collect all the ballots. For transparent and easy to vote on each agenda. In the ballot will show name of shareholder/proxy name. The number of shares eligible to vote is 1 share actual 1 vote.

Form B will not receive a ballot if the shareholder has already voted. The company will vote according to the wishes of the shareholders.

The resolution of the meeting on each agenda item. The majority of the shareholders attending the meeting and casting their votes, except

Agenda 3 must be approved by a vote of not less than thirds-fourth of the total number of votes of shareholders attending the meeting and have the right to vote.

Agenda 4 must be approved by a vote of not less than thirds-fourth of the total number of votes of shareholders attending the meeting and have the right to vote.

Since the matters proposed to the Extraordinary General Meeting of Shareholders No. 1/2021, agenda 2 to agenda 5, are related matters, therefore, in considering such agenda, if any agenda is not approved by the meeting shareholder There will be no consideration of other agenda in the next order and it will be considered that the agenda approved by the shareholders' meeting will be cancelled.

- To ensure that the meeting would understand the voting procedures when considering each matter on the agenda, Company Secretary explained the voting procedures as follows:

How to use the ballot is on each agenda item when the Chairman discusses the agenda and have requested a resolution of the meeting. Shareholders can mark 1 point for your vote. (X or ✓) on that agenda is only one slot

with your signature and drop in the box where the staff will walk to collect the ballot. (The ballots marked with more than one box are voided ballot.) The number of shareholders in each agenda may not be equal. Because there are additional shareholders register to attend the meeting.

For quick and easy for counting. The company will collect only the shareholders who voted in case of disapproval or abstain. By the shareholders can raise their hands to the staff to collect ballots. The effect of votes on each agenda. It will be shown to the shareholders on the screen. When the meeting finished, please send the remaining ballots to the staff.

3. Methods of counting

3.1 If no shareholders against or different opinion, the meeting will accept agreed.

3.2 Proxy voting agenda by shareholders will count vote as per the proxy, whether the grantee is not in the meeting

3.3 Proxy voting agenda who also did not vote, will agreed for that agenda whether the grantee in not in the meeting, unless the proxy to comment otherwise.

3.4 The shareholders who are registered already, if they are not in the meeting. We will approve the vote agreed.

When declared closed voting, the cards that arrived after the announcement closed those are approved vote.

4. The Chairman requested that each shareholder introduce himself or herself, giving his or her name and surname when asking questions or expressing opinions on any matter on the agenda, so that the relevant information could be recorded in the minutes of the meeting. Ask for cooperation, offer comments, or questions which match the agenda. If you would like to ask for something point, please ask on the final agenda.

5. In offering comments or questions for the proposed direct and concise to provide for an effective meeting, the company reserves the right to take appropriate action.

Remark: When the meeting finished, please send ballot cards remaining to staff for the monitoring.

The Chairman commenced the meeting on the following agenda;

**Agenda 1 To adopt the minutes of the Annual General Meeting of Shareholders for the year 2021**

The Chairman proposed the meeting to adopt the minutes of the Annual General Meeting of Shareholders for the year 2021 of the company to be held on April 9, 2021 that the company has provided the invitation letter sent to all shareholders.

After giving opportunities for shareholders to ask questions and express opinion but there is no question. Therefore, proposed that the meeting consider the resolution. The agenda must be approved by a majority vote of all votes of shareholders who attending the meeting and voting without counting the votes of those who abstained as a base for vote counting

**Resolution** The meeting unanimously resolved to adopt the minutes of the Annual General Meeting of Shareholders for the year 2021 as proposed.

Approved by	298,408,624	votes	Percentage of	100.0000
Disapproved by	-	votes	Percentage of	0.0000
Abstained by	-	votes	Percentage of	0.0000
Voided Ballots	-	votes	Percentage of	0.0000

**Agenda 2 To consider and approve the issuance and allocation of warrants to purchase newly issued ordinary shares of the Company Business Alignment Public Company Limited No. 1 (BIZ-W1) in the amount not exceeding 40,000,000 units to the existing shareholders of the Company in proportion to their shareholding by free of charge**

The Chairman informed the meeting that In order to prepare the company to have financial flexibility for expanding the business in the implementation of various projects and to reserve for use as working capital for the company. and/or the capital increase in the subsidiary This will help strengthen the Group’s overall capital base. and to create readiness for future operations which will lead to increased income and bring benefits to the company and its shareholders. Therefore, the Company intends to issue warrants to purchase the Company’s newly issued ordinary shares. Business Alignment Public Company Limited No. 1 (BIZ-W1) (“Warrants” or “BIZ-W1 Warrants”) in the amount not exceeding 40,000,000 units to the existing shareholders of the Company. according to shareholding proportion (Rights Offering) free of charge at the allocation rate of 10 existing ordinary shares per 1 unit of warrant. If the fraction of shares or warrants are calculated according to the allocation rate round off. The warrants are valid for 1 year from the date of issuance of the warrants. and determines the exercise price of the warrants equal to 7.00 baht per share, the exercise ratio is 1 unit of warrant per 1 newly-issued ordinary share By setting the date for determining the names of shareholders who are entitled to allocate BIZ-W1 warrants on October 28, 2021 (Record date) and setting the date for allocation of BIZ-W1 warrants on November 3, 2021. The conditions and details of the warrants BIZ-W1 appear in the summary of the warrants to purchase the newly issued ordinary shares of the Company. Business Alignment Public Company Limited No. 1 (BIZ-W1) as per the attachment No. 2 in the invitation letter that has been sent to the shareholders.

In addition, the chairman had addressed the attendees in the meeting that the company has hired Fin Plus Advisory Company Limited as a financial advisor and giving opinions regarding the issuance and allocation of warrants to purchase newly issued ordinary shares to Business Alignment Public Company Limited No. 1 (BIZ-W1) Therefore, the chairman invited a representative from Fin Plus Advisory Company Limited to present information concerning the issuance of warrant for BIZ-W1 in which the financial advisor presented the following: a summary of the objective for this warrant, details of the warrant, the effects to shareholders regarding the issuance of warrants, and timeline to process. This information is available in the capital fundraising report (F53-4) and the main points summary of warrants to purchase newly issued ordinary shares of the Company Business Alignment Public Company Limited No. 1 (BIZ-W1) which had been distributed to the shareholders in the third and second order inside the meeting invitation respectively.

After the financial advisor had presented the information to the meeting, the chairman asked the attendees to consider approving issuance and allocation of warrants BIZ-W1 of not more than 40,000,000 units for the existing shareholders of the company in accordance with the percentage share while disregarding the value. As well as to grant the approval for the board and/or the person that the board assigns to have the authority in considering amendments, terms and conditions amendment, and details involves this issuance and allocation of warrants BIZ-W1 such as the date of the warrant’s issuance, method of the warrant’s issuance, period for exercising the right, and end date for exercising the right. This approval shall cover the board and/or the person given the authority by the board to have the authority to

specify the cause of new common share issuance to be compatible with the change in price for exercising the right and/or the rate in exercising the right of this warrant, including the authority to sign and amend any documents involve and proceed with any related or required process in a reasonable manner for the success of the warrant issuance. This shall include, but not limited to request filing, information sharing, and document submission to the Securities and Exchange Commission of Thailand, the Stock Exchange of Thailand, Thailand Securities Depository Company Limited, Ministry of Commerce, and other related parties which would extend to the listing of BIZ-W1 warrant and common share created by exercising the right of the warrant in MAI Stock Exchange.

The chairman had given the opportunity for shareholders to inquire and comment regarding this matter which can be summarized as follow.

Ms. Supatra Sittichai, a shareholder, had inquired the reasoning for the company to issue the warrant instead of issuing a bond. Currently, bond had a relatively cheap interest and issuing the warrant will influence the proportion of shares.

The chairman had invited Mr. Seksan Tanopajai, a financial advisor, to address the meeting.

Mr. Seksan Tanopajai, a financial advisor, had addressed the attendees the reasoning for the company to issue a warrant instead of a bond, was because the warrant has a validity period of 1 year in which the management had aligned that the capital received from this warrant will be in effect in the year 2022. This was in-line with spending plan of the company where the capital received from this fundraising will be used in company's subsidiaries. In the past, the subsidiaries have loaned capital from the financial institution to be used in Cancer Alliance Hospital Sriracha's project which has accumulated liabilities in the form of interests. Thus, the management agreed that if this interest can be reduced, Cancer Alliance Hospital Sriracha will become profitable which will increase the turnover for the company.

Moreover, the company will use the capital received from this warrant issuance BIZ-W1 as capital reserve for various projects as the past projects have been using capital from financial institution which consists of fees and interests. Thus, the company agreed to change the source of funding from the financial institution to capital raised from shareholders. This will enable the company to reduce fees and interests. The company will turn a profit and able to pay dividends to shareholders which will maximize the benefits of all shareholders. In addition, the warrant has a validity period of 1 year where shareholders can plan their capital for the right to exercise the warrant. However, if any shareholders are not ready to exercise their rights according to the warrant, shareholders may sell their warrants to the stock exchange.

Mr. Voravid Silapusid, Chief Financial Officer and Nomination and Remuneration Committee, had given additional information that the warrant issuance will not affect the proportion of the shares because every shareholder will receive the warrant based on the proportion of the shares. In the case where the existing shareholder use the warrant in full amount, the company had given an opportunity for shareholders to make a choice whether to keep their proportion of shares or not. Shareholders may choose to exercise the right to buy common shares based on the warrant or sell the warrant to the stock exchange.

Mr. Vipoota Trakulhoon, Independent Director, had given additional input on bond issuance by stating that the cost of the bond issuance is higher than taking loans from financial institution. Currently, the company had no credit rating which will cause the interest rate for the bond to be higher than the interest from taking loans from the financial institution.

Therefore, the warrant issuance based on the existing shareholders' proportionate shares was suitable and provide benefits to the shareholders.

Ms. Supatra Sittichai, a shareholder, had inquired further in regard to the case of spending capital to help the company’s subsidiaries or Cancer Alliance Hospital Sriracha. The shareholder asked how much debt or liabilities from taking the loans are there and when will the liabilities be cleared from the account.

Mr. Voravid Silapusid, Chief Financial Officer and Nomination and Remuneration Committee stated that Cancer Alliance Hospital Sriracha had debt or liabilities from taking loans totaled at 250,000,000 baht and the liabilities will be cleared within approximately 7 years.

Mr. Nara Sripetch, a shareholder appointing the proxy who was a proxy from Thai Investor Association, had inquired whether the Cancer Alliance Hospital Sriracha has a plan to expand the project or not and what is the future direction of this project.

Mr. Sompong Chunekitiyanone, Chief Executive Officer had stated that the Cancer Alliance Hospital currently receives a BOI where the hospital has a low profit due to interests from loans. However, if the hospital acquires the capital to support its financial, the hospital will have a higher profit. Within the 8 years that the hospital receives the BOI, the hospital will not need to pay taxes which will make the turnover of Cancer Alliance Hospital Sriracha improves. This is one of the reasons why the company has chosen to issue a warrant. Moreover, Mr. Sompong Chunekitiyanone had addressed that if the hospital project goes well, there is a plan for expansion in which the success depends on the opportunity. If there is capital reserve, the hospital will be able to develop long-term.

As there were no further questions from the shareholders, the chairman asked the meeting to consider and vote. This agenda must be approved by a majority vote of the shareholders who attend the meeting and cast their votes without counting the votes of those who abstained as a base for vote counting.

**Resolution:** The meeting has considered Therefore, it was unanimously resolved to approve the issuance and allocation of BIZ-W1 warrants in the amount not exceeding 40,000,000 units to the existing shareholders of the Company in proportion to their shareholding. free of charge at the allocation rate of 10 existing ordinary shares per 1 unit of warrant and determines the exercise price of the warrants equal to 7.00 Baht per share, the exercise ratio is 1 unit of warrant per 1 newly-issued ordinary share and assignments to the Board of Directors and/or persons assigned by the Board of Directors have the power to perform various actions as detailed as proposed above

Approved by	298,408,624	votes	Percentage of	100.0000
Disapproved by	-	votes	Percentage of	0.0000
Abstained by	-	votes	Percentage of	0.0000
Voided Ballots	-	votes	Percentage of	0.0000

**Agenda 3 To consider and approve the increase of the Company’s registered capital in the amount of 20,000,000 Baht from the original registered capital of 200,000,000 Baht to a registered capital of 220,000,000 baht by issuing 40,000,000 new ordinary shares with a par value of 0.50 Baht per share**

The chairman informed the meeting that because the company intends to issue and allocate warrants to purchase the company’s newly issued common shares of Business Alignment Public Company Limited No. 1 (BIZ-W1) in the amount of not more than 40,000,000 units to the existing shareholders of the company in proportion to their respective shareholdings (Rights Offering), as detailed in agenda 2 above. Therefore, it is appropriate to propose to the meeting to consider and approve the increase of the registered capital of the company in the amount of 20,000,000 baht from the original registered capital of 200,000,000 baht to the registered capital of 220,000,000 baht by issuing 40,000,000 new common shares at par value for 0.50 baht per share to support the exercise of rights under BIZ-W1 warrants in the amount not exceeding 40,000,000 units. Details of the issuance and allocation of newly issued common

shares appear in the capital increase report form (F53-4) come with number 3 in the invitation letter that has been sent to the shareholders.

The chairman had given the opportunity for shareholders to inquire and express their opinions.

There were no questions or comments from the shareholders. The chairman asked the meeting to consider and vote. In this agenda, votes of approval must be cast with a vote of not less than three-fourths of the total votes of the shareholders attending the meeting and having the right to vote by counting the votes of those who abstained as a base for vote counting.

**Resolution:** The meeting has considered Therefore, it was unanimously resolved to approve the increase of the Company’s registered capital of 20,000,000 Baht from the original registered capital of 200,000,000 baht to a registered capital of 220,000,000 Baht by issuing 40,000,000 new ordinary shares with a par value of 0.50 Baht per share as proposed.

Approved by	298,408,624	votes	Percentage of	100.0000
Disapproved by	-	votes	Percentage of	0.0000
Abstained by	-	votes	Percentage of	0.0000
Voided Ballots	-	votes	Percentage of	0.0000

**Agenda 4 To consider and approve the amendment of the Company’s Memorandum of Association Clause 4. Re: Registered Capital to be in line with the company’s registered capital increase**

The Chairman informed the meeting that in order to be consistent with the increase of registered capital of the Company in the amount of 20,000,000 Baht, as detailed above in Agenda 3 above, it is therefore appropriate to propose to the meeting to consider and approve the amendment of the Company’s Memorandum of Association Clause 4. Re: Registered Capital. Instead, use the following text.

“Clause 4.	Registered Capital Amount	220,000,000	Baht
	divided into	440,000,000	Shares
	par value	0.50	Baht
	separated into		
	common stock	440,000,000	Shares
	Preferred shares	-	Shares

In this regard, the person was assigned by the Board of Directors to register the amendment of the Memorandum of Association of the Company to the Department of Business Development, Ministry of Commerce has the authority to amend and add words to comply with the registrar’s order.

The chairman has given the opportunity for shareholders to inquire and express their opinions.

There were no questions or comments from the shareholders, the Chairman asked the meeting to consider and vote. In this agenda, votes of approval must be cast with a vote of not less than three-fourths of the total votes of the shareholders attending the meeting and having the right to vote by counting the votes of those who abstained as a base for vote counting.

**Resolution:** The meeting has considered; it was unanimously resolved to approve the amendment of Clause 4 of the Company’s Memorandum of Association regarding the registered capital. to be in line with the company’s registered capital increase and delegating to the person assigned by the Board of Directors to register the amendment of the Memorandum of Association of the Company to the Department of Business Development Ministry of Commerce have the power to amend and add words to comply with the order of the Registrar as proposed

Approved by	298,408,624	votes	Percentage of	100.0000
Disapproved by	-	votes	Percentage of	0.0000
Abstained by	-	votes	Percentage of	0.0000
Voided Ballots	-	votes	Percentage of	0.0000

**Agenda 5 To consider and approve the allocation of not more than 40,000,000 newly issued ordinary shares with a par value of 0.50 baht per share to support the exercise of the warrants to purchase the newly issued ordinary shares of Business Alignment Public Company Limited No. 1 (BIZ-W1)**

The chairman informed the meeting that because the company intends to increase the registered capital of the company in the amount of 20,000,000 baht by issuing 40,000,000 new common shares with a par value of 0.50 baht per share to support the exercise of BIZ-W1 warrants in the amount of not more than 40,000,000 units. As details mentioned in Agenda 3 above, it is therefore appropriate to propose to the Meeting to consider and approve the allocation of not more than 40,000,000 newly issued common shares with a par value of 0.50 baht per share to support the exercise of the warrants not more than 40,000,000 units of BIZ-W1 issued to the existing shareholders of the Company in proportion to their respective shareholdings (Rights Offering) free of charge in the allocation ratio of 10 existing common shares per 1 unit of the warrant. If the fraction of shares or warrants is calculated according to the allocation rate round off, the exercise price of the warrants is set at 7.00 baht per share, the exercise ratio is 1 unit of warrant per 1 newly-issued common share. Details of the issuance and allocation of newly-issued common shares appear in the capital increase report form. (F53-4) Enclosure No. 3 in the invitation letter that had been sent to the shareholders.

The chairman had given the opportunity for shareholders to inquire and comment regarding this matter which can be summarized as follow.

Ms. Supattra Sittichai, a shareholder, in conclusion, has inquired in the event that the rights to purchase newly issued common shares of the company under the warrants have been exercised for the first time, Will the newly issued common shares be added the investor's portfolio immediately? Or the newly issued common shares will be added to the investor's portfolio on the last exercise date?

Mr. Seksan Tanopajai, a financial advisor, clarified, in conclusion, that the newly issued common shares will be added to the investor's portfolio from the first exercise of the rights to purchase the company's newly issued common shares under the warrants after payment had been made which must be carried out in accordance with the procedures of the Stock Exchange of to list the newly issued common shares on the Market for Alternative Investment (MAI)

As there were no further questions from the shareholders, the chairman asked the meeting to consider and vote. This agenda must be approved by a majority vote of the shareholders who attend the meeting and cast their votes without counting the votes of those who abstained as a base for vote counting.

**Resolution:** The meeting has considered Therefore, it was unanimously resolved to approve the allocation of not more than 40,000,000 newly issued ordinary shares with a par value of 0.50 Baht per share to support the exercise of the warrants to purchase the newly issued ordinary shares of Business Alignment Public Company Limited No. 1 (BIZ-W1) as proposed

Approved by	298,408,624	votes	Percentage of	100.0000
Disapproved by	-	votes	Percentage of	0.0000
Abstained by	-	votes	Percentage of	0.0000
Voided Ballots	-	votes	Percentage of	0.0000



**Agenda 6 To consider any other business (if any)**

No other business matter was proposed to the meeting for consideration. however, there were questions raised by the shareholders as the following summary questions:

Ms. Supattra Sittichai, a shareholder, had a further inquiry regarding the progress of the hospital project.

Mr. Sompong Chunekitiyanone, Chief Executive Officer clarified, in conclusion, that the progress of the hospital project has been operating well, especially in the radiation to the patient. Currently, the hospital is able to handle 48 to 50 patients per day, which exceed the company's expectation. As for the chemotherapy treatment, the chemotherapy had not met the target of the company as patients are more likely to be admitted to public hospitals. The company will try to control the expenses in this respect to meet the company's goal. Mr. Sompong Chuenkitiyanon provided additional information that at present, medicinal cannabis is being used by cancer patients to improve the quality of life of patients such as being able to eat and sleep better.

For the company's business, currently, the company had been studying innovations regarding medical examination utilizing DNA, which the company had been studying for about 2 years. It is expected that at the beginning of next year the progression would be more concrete since there appeared to be a time required to understand and prepare both personnel and patients.

Mr. Nara Sripetch, a shareholder appointing the proxy who was a proxy from Thai Investor Association, had a further inquiry, in conclusion, regarding the number of business operators using medical cannabis for cancer patients and academic reports or research supporting whether cannabis can treat or inhibit cancer cells.

Mr. Sompong Chunekitiyanone, Chief Executive Officer clarified, in conclusion, that, at present, there appear to be no academic reports or research supporting that cannabis can treat or inhibit cancer cells, however, medical cannabis is used in cancer patients only as complements for standard cancer treatment. The standard treatment for cancer patients is chemotherapy, radiation therapy, or surgery since cancer patients who suffer the most from chemotherapy are insomnia and appetite diminishing, which medical cannabis could be a supplement to allow patients to be able to eat and sleep better. For the business operator using medical cannabis, Mr. Sompong Chunekitiyanone clarified, in conclusion, that in many hospitals, there is a growing interest in using cannabis as a supplement to treat patients, which is not only for cancer patients. In addition, at present, the company does not process cannabis use with patients other than cancer patients, which is the company's specialty.

There were no further questions and comments. The Chairman thanked all shareholders for sacrificing their time to attend the meeting.

The meeting was adjourned at 3.00 p.m.

Signed by \_\_\_\_\_ - signed - \_\_\_\_\_ Chairman of the Meeting  
Mr. Woodtipong Moleechad  
Chairman of the Board

Signed by \_\_\_\_\_ - signed - \_\_\_\_\_ The meeting record  
Ms. Srisunun Anuchornphan  
Company Secretary